IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Sanofi Drops Autoimmune Drug Partnered with Nurix

Sanofi has decided to stop developing an experimental autoimmune disease treatment created with Nurix Therapeutics. The decision ends potential milestone payments and royalties, causing Nurix shares to plunge.

Xurve View
Insights:
FILE PHOTO: The Sanofi logo is shown at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake/File Photo

Nurix Therapeutics shares plunged 38% in extended trading after Sanofi halted development of an experimental autoimmune drug. The termination wipes out prospective milestone payments and royalties tied to the program. The setback hits the United States biotech firm as it advances other partnered and internal pipelines.